Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and
the fifth most common cancer worldwide. Most of these patients are seen with advanced …

The cancer mortality rate of hepatocellular carcinoma (HCC) is the second highest in the
world and the therapeutic options are limited. The incidence of this deadly cancer is rising at …

Background Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world.
Having a very poor prognosis, it currently ranks as the third most common cause of cancer …

Hepatocellular carcinoma (HCC) is the 5th most common malignancy which is responsible
for more than half million annual mortalities; also, it is the third leading cause of cancer …

Hepatocellular carcinoma (HCC) is one of the primary causes of cancer-associated deaths
worldwide. Current treatment methods include surgical resection, chemotherapy and …

Hepatocellular carcinoma (HCC) is an aggressive malignancy and the second leading
cause of cancer-related deaths worldwide. Conventional biomarkers exhibit poor …

Intracellular lipid droplets (LDs) are remarkably dynamic and complex organelles that enact
regulated storage and release of lipids to fulfil their fundamental roles in energy metabolism …

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third
leading cause of cancer-related death. Because of the fast growth, early hepatic metastasis …

Sorafenib is the only and standard systematic chemotherapy drug for treatment of advanced
hepatocellular carcinoma (HCC) at the current stage. Although sorafenib showed survival …

In some countries where the Model for End-Stage Liver Disease (MELD) score is used for
graft allocation, selected patients with hepatocellular carcinoma (HCC) receive a fixed …